Prestige Consumer Healthcare (NYSE:PBH) Releases Quarterly Earnings Results, Misses Expectations By $0.16 EPS

Prestige Consumer Healthcare (NYSE:PBH) issued its quarterly earnings data on Wednesday. The company reported $1.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.39 by ($0.16), FiscalAI reports. The firm had revenue of $281.62 million for the quarter, compared to analysts’ expectations of $293.64 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The firm’s revenue was down 5.0% on a year-over-year basis. During the same period last year, the company earned $1.32 earnings per share. Prestige Consumer Healthcare updated its FY 2027 guidance to 4.420-4.510 EPS.

Prestige Consumer Healthcare Trading Down 10.3%

Shares of NYSE:PBH traded down $5.32 on Thursday, hitting $46.49. 1,306,000 shares of the company’s stock were exchanged, compared to its average volume of 485,532. Prestige Consumer Healthcare has a 12 month low of $42.62 and a 12 month high of $89.37. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of 12.37, a price-to-earnings-growth ratio of 1.51 and a beta of 0.40. The business’s 50 day simple moving average is $58.79 and its two-hundred day simple moving average is $61.60. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93.

Analyst Ratings Changes

PBH has been the topic of several recent research reports. Jefferies Financial Group decreased their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a report on Friday, January 30th. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $74.75.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares in the company, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp grew its position in shares of Prestige Consumer Healthcare by 1.4% during the 4th quarter. State Street Corp now owns 1,992,497 shares of the company’s stock worth $122,917,000 after buying an additional 27,721 shares in the last quarter. Morgan Stanley grew its position in shares of Prestige Consumer Healthcare by 6.3% during the 4th quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock worth $74,209,000 after buying an additional 71,078 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Prestige Consumer Healthcare by 5.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company’s stock worth $45,568,000 after buying an additional 35,126 shares in the last quarter. Bank of America Corp DE grew its position in shares of Prestige Consumer Healthcare by 19.1% during the 2nd quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock worth $57,601,000 after buying an additional 115,459 shares in the last quarter. Finally, Raymond James Financial Inc. grew its position in shares of Prestige Consumer Healthcare by 15.7% during the 3rd quarter. Raymond James Financial Inc. now owns 637,932 shares of the company’s stock worth $39,807,000 after buying an additional 86,373 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).